chemic
modif
protein
bovin
serum
albumin
chicken
lysozym
anhydrid
yield
compound
exert
antivir
activ
vitro
compar
nativ
unmodifi
protein
three
envelop
virus
test
human
herp
simplex
viru
type
bovin
parainfluenza
viru
type
porcin
respiratori
corona
viru
prove
sensit
chemic
modifi
protein
present
antivir
activ
assay
infect
howev
achiev
inhibit
significantli
higher
concentr
modifi
protein
requir
present
infect
compar
infect
result
suggest
multipl
mechan
involv
inhibit
infect
proteolyt
digest
albumin
lysozym
trypsin
chymotrypsin
pepsin
yield
sever
peptid
fragment
antiherpet
activ
chemic
modif
peptid
fragment
gener
peptid
antivir
activ
howev
almost
alway
combin
cytotox
effect
vero
cell
overal
result
suggest
target
chemic
modif
natur
product
might
provid
compound
effect
infect
current
chemotherapeut
antivir
drug
characteris
mani
case
limit
clinic
efficaci
suboptim
pharmacokinet
toxic
side
effect
patick
pott
respons
number
recent
studi
investig
potenti
benefit
use
natur
occur
compound
therapeut
antivir
agent
herp
simplex
viru
type
marchetti
et
al
isaac
et
al
seongku
et
al
carlucci
et
al
wachsman
et
al
previou
studi
demonstr
presenc
antivir
agent
milk
matthew
et
al
newburg
et
al
one
agent
lactoferrin
shown
later
inhibit
human
immunodefici
viru
human
cytomegaloviru
respiratori
syncyti
viru
polioviru
rotaviru
vitro
harmsen
et
al
marchetti
et
al
marchetti
et
al
marchetti
et
al
superti
et
al
swart
et
al
valenti
et
al
viani
et
al
highlight
import
natur
occur
protein
antivir
agent
report
inhibit
vitro
polyanion
substanc
heparin
sulphat
polysaccharid
ueno
kuno
baba
et
al
lederman
et
al
encourag
sever
group
investig
antivir
activ
chemic
modifi
protein
introduct
neg
charg
human
serum
albumin
chemic
modif
polysaccharid
formaldehyd
aliphat
anhydrid
yield
compound
antivir
activ
jansen
et
al
jansen
et
al
takami
et
al
kuiper
et
al
kuiper
et
al
swart
et
al
swart
et
al
howev
systemat
studi
neurath
et
al
demonstr
aromat
anhydrid
effect
convers
natur
protein
neg
charg
antivir
agent
cellular
lymphocyt
macrophag
monocyt
found
primari
target
inhibit
modifi
anhydrid
higher
concentr
also
bind
hiv
bind
site
neurath
et
al
addit
activ
neurath
et
al
chlamydia
trachomati
previous
shown
antimicrobi
peptid
could
gener
digest
aprotinin
pellegrini
et
al
pellegrini
et
al
lysozym
pellegrini
et
al
pellegrini
et
al
pellegrini
et
al
proteolyt
digest
aprotinin
yield
hexapeptid
antivir
activ
bovin
parainfluenza
viru
pellegrini
et
al
present
studi
aim
investig
antivir
activ
fragment
result
proteolyt
digest
nativ
protein
chemic
modif
anhydrid
follow
protein
use
chemic
modif
bovin
serum
albumin
bsa
fluka
lysozym
chicken
egg
white
fluka
sigma
chemic
co
st
loui
mo
sigma
anhydrid
use
chemic
reagent
modif
protein
obtain
aldrich
nucleosil
revers
phase
chromatographi
macherynagel
dialys
membran
spectrapor
mwco
spectrum
laboratori
inc
steril
filter
millex
gp
millipor
herp
simplex
viru
type
gift
dr
wunderli
institut
medic
virolog
univers
bovin
parainfluenza
viru
type
porcin
respiratori
corona
viru
prcv
avail
institut
virolog
three
virus
titrat
inocul
cell
dilut
use
endpoint
dilut
method
reed
muench
cell
use
measur
antivir
activ
madindarbi
bovin
kidney
cell
mdbk
swine
testicular
st
cell
use
measur
inhibitori
effect
chemic
modifi
protein
prcv
respect
origin
purchas
atcc
cell
mdbk
cell
grown
eagl
minim
essenti
medium
mem
lglutamin
gibcobrl
supplement
foetal
calf
serum
fc
gibcobrl
uml
penicillin
gml
streptomycin
gibcobrl
st
cell
cultur
medium
contain
nonessenti
amino
acid
nea
gibcobrl
mm
sodiumpyruv
gibcobrl
cellmainten
foetal
calf
serum
concentr
lower
st
cell
cell
mdbk
cell
respect
protein
dissolv
trifluoroacet
acid
vv
purifi
revers
phase
chromatographi
nucleosil
column
use
linear
gradient
acetonitril
ml
vv
trifluoroacet
acid
protein
modifi
anhydrid
accord
procedur
describ
neurath
et
al
briefli
mg
purifi
protein
dissolv
ml
naphosph
ph
anhydrid
solut
ad
eight
aliquot
l
mgml
dissolv
dimethylsulfoxyd
min
interv
ph
solut
maintain
h
incub
c
mixtur
dialys
twice
ml
pb
ph
protein
concentr
determin
photometr
describ
gill
von
hippel
fifti
milligram
protein
mg
trypsin
dissolv
ml
tra
triethanolaminehcl
buffer
contain
mm
cacl
ph
mixtur
stir
h
c
solut
acidifi
ad
l
trifluoroacet
acid
vv
centrifug
g
min
supernat
previou
step
load
run
onto
nucleosil
column
previous
equilibr
trifluoroacet
acid
acetonitril
one
hundr
microlit
load
everi
run
column
elut
flow
rate
mlmin
fraction
l
collect
collect
fraction
linear
gradient
acetonitril
appli
fraction
pool
accord
elut
diagram
pool
divid
two
sampl
freezedri
one
two
sampl
dissolv
pb
assay
antivir
activ
sampl
treat
describ
chymotrypt
digest
protein
separ
chymotrypt
fragment
perform
experiment
condit
report
tryptic
digest
protein
fraction
revers
phase
chromatographi
pool
accord
elut
diagram
treat
describ
fifti
milligram
protein
mg
pepsin
dissolv
ml
citrat
buffer
ph
mixtur
gentli
stir
h
c
enzymat
reaction
stop
heat
sampl
c
min
sampl
centrifug
g
min
separ
peptic
fragment
perform
revers
phase
chromatographi
nucleosil
column
describ
fraction
revers
phase
chromatographi
pool
accord
elut
diagram
treat
describ
section
tryptic
digest
protein
singl
pool
sampl
deriv
proteolyt
digest
albumin
lysozym
trypsin
chymotrypsin
pepsin
freezedri
dissolv
ml
naphosph
buffer
ph
thirtyf
microlit
solut
mgml
dmso
ad
time
time
interv
min
room
temperatur
solut
incub
h
room
temperatur
ph
solut
maintain
ph
reaction
sampl
dialys
spectrapor
mwco
l
pb
h
final
filter
membran
sampl
assay
antivir
activ
describ
antivir
assay
neutral
red
uptak
assay
neutral
red
uptak
assay
perform
follow
similar
procedur
describ
borenfreund
puerner
briefli
h
infect
mainten
medium
remov
cell
incub
h
mem
contain
gml
neutral
red
fluka
lwell
cell
wash
fix
l
formaldehyd
cacl
neutral
red
extract
l
acet
acid
ethanol
absorb
measur
nm
dynatech
micropl
reader
percent
protect
achiev
compound
infect
cell
calcul
describ
pauwel
et
al
sampl
test
triplic
test
compound
dissolv
mem
incub
confluent
cell
monolay
tissu
cultur
plate
nunc
increas
concentr
gml
mgml
h
c
co
remov
test
compound
cell
wash
phosphatebuff
salin
pb
infect
tcid
well
correspond
multipl
infect
moi
tcid
well
prcv
correspond
moi
respect
h
incub
unadsorb
viru
remov
cell
monolay
wash
pb
incub
mem
cytophat
effect
visibl
h
uninfect
cell
incub
test
substanc
alon
evalu
cytotox
inhibit
cytopath
effect
assess
light
microscopi
measur
neutral
red
uptak
assay
control
consist
infect
untreat
vero
cell
monolay
assay
perform
follow
protocol
describ
except
test
compound
ad
togeth
viru
incub
time
h
c
co
solut
contain
compound
virus
remov
cell
monolay
wash
pb
incub
mem
h
assay
carri
report
follow
differ
first
cell
monolay
infect
viru
h
incub
unadsorb
viru
remov
cell
monolay
wash
pb
incub
test
compound
mem
h
quantif
inhibit
perform
viru
yield
inhibit
assay
accord
procedur
report
gilfernandez
et
al
aboudi
et
al
confluent
cell
monolay
plate
treat
compound
viru
infect
describ
h
incub
c
co
plate
frozen
thaw
three
time
confluent
cell
monolay
grown
plate
nunc
inocul
dilut
supernat
h
c
co
remov
inoculum
monolay
wash
pb
overlaid
mem
supplement
carboxi
methyl
cellulos
fluka
fc
uml
penicillin
gml
streptomycin
incub
c
co
day
methylcellulos
medium
remov
monolay
fix
methanol
stain
crystal
violet
plaqu
number
count
result
express
percentag
plaqu
inhibit
comparison
untreat
control
cell
monolay
ec
ec
concentr
need
achiev
plaqu
reduct
compar
untreat
infect
cell
monolay
determin
directli
curv
obtain
plot
inhibit
viru
yield
concentr
sampl
data
present
result
repeat
experi
perform
triplic
confluent
cell
monolay
grown
cell
cultur
plate
incub
twofold
serial
dilut
test
compoundsstart
concentr
gml
mgmlfor
h
c
co
time
cell
viabil
evalu
neutral
red
uptak
assay
light
microscopi
percent
cell
surviv
calcul
ratio
treat
uninfect
cellsuntr
uninfect
cell
express
percentag
valu
plot
concentr
test
compound
concentr
need
caus
cytotox
cc
determin
graphic
aysi
et
al
sampl
test
triplic
inhibit
cytopath
effect
nativ
chemic
modifi
protein
evalu
viru
infect
albumin
lysozym
show
antivir
activ
either
prcv
respect
contrast
modifi
protein
ie
show
antivir
activ
prcv
fig
shown
inhibit
cytopath
effect
three
experi
ie
present
fig
fig
infect
fig
show
minim
inhibit
incub
monolay
infect
wherea
inhibit
evid
compound
present
infect
data
shown
antivir
activ
modifi
protein
quantifi
determin
viru
yield
h
post
infect
treat
untreat
cell
test
compound
present
infect
step
modifi
protein
afford
potent
inhibit
replic
fig
tabl
attempt
find
whether
pretreat
cell
modifi
protein
result
inhibit
viru
yield
cultur
incub
h
test
compound
remov
infect
preincub
cell
inhibit
almost
complet
viru
yield
concentr
mgml
fig
reduc
viru
yield
almost
complet
concentr
mgml
inhibit
yield
assay
concentr
ec
valu
determin
yield
complet
inhibit
viru
multipl
assay
concentr
mgml
ec
valu
determin
rang
gml
gml
wherea
ec
valu
rang
gml
gml
tabl
si
select
index
si
cc
ec
compound
present
infect
cell
monolay
b
compound
present
infect
cell
monolay
c
compound
present
infect
cell
monolay
nd
determin
cc
concentr
compound
reduc
cell
viabil
b
ec
concentr
compound
reduc
yield
c
ec
concentr
compound
reduc
yield
compound
prove
potent
inhibitor
multipl
titrat
curv
antivir
activ
compound
investig
fig
show
similar
slope
less
effect
low
concentr
compar
howev
assay
concentr
mgml
inhibit
complet
activ
caus
distinct
reduct
viru
yield
alreadi
concentr
gml
although
toxic
vero
cell
potent
inhibitor
ec
valu
gml
wherea
weakest
inhibitor
ec
gml
ec
valu
rang
gml
gml
tabl
order
evalu
antivir
activ
viral
adsorpt
incub
infect
cell
monolay
h
post
infect
h
result
report
tabl
shown
fig
strongli
inhibit
viral
multipl
assay
concentr
mgml
inhibit
viru
product
alreadi
concentr
gml
potent
inhibitor
ec
valu
gml
wherea
weakest
inhibitor
ec
valu
gml
ec
valu
rang
gml
gml
tabl
investig
antivir
activ
show
cytotox
effect
cell
h
incub
cc
valu
determin
neutral
red
uptak
assay
mgml
wherea
compound
caus
cytotox
effect
concentr
mgml
tabl
select
index
valu
rang
lysozym
antivir
activ
determin
pool
deriv
proteolyt
digest
protein
albumin
lysozym
test
neutral
red
uptak
assay
perform
proteolyt
digest
albumin
lysozym
trypsin
result
mixtur
sever
fragment
could
partial
separ
revers
phase
chromatographi
elut
diagram
revers
phase
chromatographi
digest
protein
pool
fraction
shown
fig
antivir
test
perform
assay
pool
viral
infect
cell
monolay
preincub
pool
deriv
tryptic
digest
albumin
lysozym
vero
cell
viru
infect
afford
inhibit
cytopath
effect
pool
simultan
incub
viru
inhibit
cytopath
effect
observ
pool
vi
deriv
albumin
cell
protect
pool
ix
cell
protect
howev
pool
highli
cytotox
vero
cell
surviv
upon
incub
antivir
activ
could
observ
almost
pool
incub
viru
infect
pool
v
deriv
tryptic
digest
albumin
show
antivir
activ
wherea
pool
iiiv
vi
weakli
inhibit
multipl
pool
vi
properti
inhibit
cytopath
effect
assay
presenc
viru
viral
infect
strongli
cytotox
pool
ii
iii
viii
result
digest
trypsin
moder
activ
cytotox
vero
cell
pool
ineffect
inhibit
cytopath
effect
antivir
activ
fragment
could
detect
pool
ii
iii
link
high
grade
toxic
vero
cell
pool
iiv
deriv
digest
lysozym
trypsin
activ
albumin
lysozym
digest
chymotrypsin
fraction
revers
phase
chromatographi
nucleosil
shown
antivir
activ
could
reveal
pool
ad
viru
infect
cell
monolay
pool
assay
either
viru
infect
show
antiherpet
activ
antivir
activ
fragment
deriv
albumin
digest
chymotrypsin
could
observ
two
pool
howev
toxic
vero
cell
almost
pool
obtain
chymotrypt
digest
inhibit
viral
replic
partial
show
moder
cytotox
effect
vero
cell
similar
result
obtain
chymotrypt
fragment
three
seven
pool
deriv
chymotrypt
digest
lysozym
show
antiherpet
activ
link
moder
cytotox
vero
cell
pool
show
antivir
activ
peptic
digest
albumin
lysozym
result
sever
peptid
fragment
could
resolv
revers
phase
chromatographi
shown
pool
show
antivir
activ
ad
viral
infect
vero
cell
monolay
fail
inhibit
cytopath
effect
present
assay
viru
infect
two
four
pool
obtain
peptic
digest
albumin
inhibit
weakli
viral
replic
ad
viral
infect
howev
show
time
moder
cytotox
effect
vero
cell
inhibitori
activ
fragment
gener
peptic
digest
present
almost
pool
one
lack
antivir
activ
activ
pool
slightli
cytotox
toward
vero
cell
pool
obtain
peptic
digest
show
inhibit
howev
cytotox
vero
cell
one
pool
obtain
digest
lysozym
pepsin
present
weak
antiherpet
activ
combin
howev
cytotox
compound
present
pool
deriv
proteolyt
digest
protein
chemic
modifi
anhydrid
describ
section
antivir
activ
chemic
modifi
pool
investig
chemic
modifi
pool
deriv
digest
albumin
lysozym
trypsin
chymotrypsin
pepsin
show
antivir
activ
incub
cell
monolay
viru
infect
almost
pool
ineffect
weakli
activ
present
viru
infect
case
pool
deriv
tryptic
digest
cell
protect
rang
among
deriv
chymotrypt
digest
weak
antiherpet
activ
detect
two
pool
deriv
deriv
peptic
digest
devoid
antiherpet
effect
data
shown
pool
show
antiherpet
effect
assay
viru
infect
case
deriv
tryptic
digest
cell
protect
rang
pool
iv
pool
ix
respect
howev
pool
inhibitori
effect
toward
also
toxic
vero
cell
deriv
chymotrypt
digest
lysozym
inhibit
cytophat
effect
contrast
deriv
chymotrypsin
digest
protein
either
inact
weakli
activ
cell
protect
rang
howev
pool
toxic
vero
cell
data
shown
deriv
peptic
digest
albumin
lysozym
show
weak
antivir
activ
cell
protect
pool
rang
data
shown
present
studi
show
protein
strongli
inhibit
multipl
thu
confirm
introduct
hydrophob
neg
charg
residu
polypeptid
chain
use
procedur
confer
antivir
activ
protein
howev
fact
protein
fail
inhibit
prcv
envelop
virus
like
indic
unspecif
damag
viru
envelop
caus
hydrophob
electroneg
interact
envelop
protein
unlik
nativ
protein
chemic
compound
alon
show
antivir
activ
viru
investig
indic
inhibit
cytopath
effect
peculiar
properti
modifi
protein
abl
inhibit
initi
spread
infect
also
protect
effect
cell
render
resist
viru
infect
howev
cell
preincub
clear
reduct
viral
multipl
could
detect
higher
concentr
assay
viru
infect
effect
prevent
viral
infect
cell
wherea
least
effect
latter
protein
inhibit
complet
maxim
concentr
use
assay
ec
ec
valu
determin
inhibit
effici
infect
vero
cell
present
infect
stage
adsorpt
penetr
virion
particl
cell
sever
viral
glycoprotein
gb
gc
gd
correspond
receptor
present
cell
membran
respons
adsorpt
penetr
wudunn
spear
herold
et
al
shieh
et
al
trybala
et
al
marchetti
et
al
cocchi
et
al
might
impli
antivir
activ
present
infect
base
interact
compound
viral
glycoprotein
support
fact
bind
antigc
monoclon
antibodi
inhibit
neurath
et
al
viru
replic
addit
effici
inhibit
infect
cell
might
one
hand
due
cell
damag
caus
viral
multipl
allow
compound
penetr
cell
mechan
postul
cystatin
c
et
al
hand
bind
modifi
protein
viral
envelop
glycoprotein
could
taken
basi
explain
inhibit
intercellular
extracellular
level
fact
bind
glycoprotein
e
neurath
et
al
mediat
togeth
gi
direct
celltocel
transmiss
dingwel
et
al
week
et
al
blockag
ge
would
inhibit
viral
spread
intercellular
level
bind
modifi
protein
glycoprotein
gb
gc
andor
gd
virion
releas
cell
first
replic
cycl
could
give
explan
extracellular
inhibit
neg
charg
hydrophob
interact
antivir
compound
viru
envelop
protein
suggest
possibl
activ
principl
antivir
activ
neurath
et
al
chemic
target
posit
charg
lysin
residu
polypeptid
chain
chemic
reaction
becom
neg
charg
neg
charg
residu
protein
highest
antivir
activ
possess
modifi
lysin
residu
five
time
less
activ
lysin
residu
assay
viral
infect
vero
cell
lysozym
half
lysin
residu
higher
antivir
activ
comparison
nevertheless
strongli
toxic
vero
cell
first
screen
antivir
compound
examin
peptid
fragment
obtain
proteolyt
digest
protein
although
singl
peptid
isol
result
show
peptid
sequenc
antivir
activ
present
protein
investig
mani
pool
test
abl
limit
viru
spread
infect
vero
cell
howev
pool
toxic
differ
extent
vero
cell
incub
h
import
presenc
peptid
sequenc
antiherpet
activ
report
neurath
et
al
confirm
extens
present
studi
therefor
want
know
whether
chemic
modif
lysin
residu
would
lead
increas
antivir
activ
peptid
fragment
gener
proteolyt
digest
instabl
precipit
acid
ph
make
purif
revers
phase
chromatographi
imposs
sinc
procedur
perform
acid
ph
thu
decid
directli
digest
chemic
modifi
peptid
fragment
present
pool
modifi
pool
show
antiherpet
activ
present
infect
vero
cell
sever
abl
block
multipl
viru
howev
examin
toxic
vero
cell
differ
extent
sinc
present
stage
research
singl
peptid
pool
antiherpet
activ
isol
possibl
say
certainti
whether
antivir
activ
toxic
effect
due
molecul
two
separ
entiti
conclus
result
confirm
modif
lysin
residu
use
technolog
develop
compound
antiherpet
activ
show
moreov
peptid
antiherpet
activ
gener
proteolyt
digest
protein
short
peptid
antivir
activ
particular
interest
synthet
peptid
low
product
cost
reduc
antigen
consequ
limit
possibl
hypersensit
